Deep Tissue Low Intensity Laser Therapy or Treatment (DT-LILT) as described here is a novel methodology through which selective destruction of nociceptive (pain) nerves can be brought upon by a medical laser delivery system using the phenomenon of absorption and cell resonance. Using this method nerve cells that transmit pain can be selectively destroyed leaving the surrounding tissues intact as no heat is generated. The delivery system incorporates a fine needle through which a 703 nm (range 690 to 710) pulsed wave low intensity laser is delivered deep into the body, directly to the area of pain causing selective destruction of pain nerves. Laser devices based on this methodology should be used only by the physician or equivalent professional community since diagnosing and defining the area of pain is critical to providing successful pain relief.

Devices and methods for restructure and stabilization of a fractured or weakened head of a bone are disclosed herein. A device includes a delivery catheter having a proximal end and a distal end, an inner void for passing at least one light sensitive liquid, and an inner lumen; an expandable member releasably engaging the distal end of the delivery catheter; and a light conducting fiber sized to pass through the inner lumen of the delivery catheter and into the expandable member. The expandable member moves from a deflated state to an inflated state when the light sensitive liquid is passed to the expandable member. When the light conducting fiber is in the expandable member, the light conducting fiber is able to disperse the light energy to initiate hardening of the light sensitive liquid within the expandable member to form a photodynamic implant.

Systems, devices, and methods are described for providing, among other things, improvement in treatment of abnormal tissues including cancer, utilizing light activated drug therapy. Improvements include the use of optical penetration and drug penetration enhancers, in combination with photosensitizing drugs, and the use of localization aids and implements, which enable treatment of larger tissue volumes using minimal tissue access. The cytotoxic photoactivation process is also improved by using internal guidance to direct the light source to and at the lesion site using a naturally occurring orifice or intravascular access route.

The present disclosure is directed to systems and methods that can apply low level light (LLL) to facilitate platelet biogenesis or extend platelet lifespan. While not wishing to be bound by theory, it is believed that LLL can enhance the ATP synthesis by the mitochondria within platelets and/or platelet precursor cells, which, thereby, helps to enhance platelet biogenesis and extend the platelet lifespan. In some instances, LLL can facilitate in vitro and/or in vivo platelet biogenesis. In other instances, LLL can extend platelet lifespan in circulation. In still other instances, LLL can be employed to prolong the shelf-life of stored platelets.

A bone implant includes a bore extending entirely through the bone implant. The bone implant also includes a light source to emit light onto bone adjacent the bone implant to stimulate bone growth and/or reduce bone loss.

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

An optical stimulation lead includes a lead body including a distal end, a distal portion, and a proximal portion; and an optical assembly attached to the distal end of the lead body. The optical assembly includes a light emitter; a feedthrough assembly including at least one ceramic block, at least one feedthrough pin extending through the at least one ceramic block and electrically coupled to the light emitter, and a metal housing attached to the at least one ceramic block; a metal tube attached to the feedthrough assembly and disposed around the light emitter; and an emitter cover disposed over the light emitter and coupled to the metal tube.

An endoscopic imaging system is disclosed that includes an endoscope having a first channel and a second channel, a high-power, multi-wavelength LED array, a digital micro-mirror device that receives light directed from the high-power, multi-wavelength LED array and generates spatial frequency patterns, and dichroic mirror that separates reflectance and fluorescence images.

Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

An optical electrode having a plurality of electrodes, including a recording electrode having a roughened surface and an optical light source configured to emit light, wherein at least a portion of the light impinges on the recording electrode. Also disclosed are methods of producing an optical electrode and an opto-electronic neural interface system.